Volver a la clasificación

Exponent, Inc. (EXPO)

NEUTRAL
IndustrialsEngineering & ConstructionUnited States

Fundamental

65

Precio

$69.78

Capitalización Bursátil

$3.39B

Parte 1 · Cuánto vale la empresa

Resumen

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$632M

Últimos 12 meses (hasta 3/7/2026)

Beneficio Neto

$112M

Últimos 12 meses (hasta 3/7/2026)

Flujo de Caja Libre

$122M

Patrimonio Neto Total

$390M

Pasivo Total

$387M

Ratio de Liquidez

1.98

Cobertura de Intereses

-

Deuda/EBITDA

0.62

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

General caseValoración Justa

Valor Justo

$63.65

Precio Actual

$69.78

Margen de Seguridad

-9.6%

Rango de Valor Justo

$45.42 - $81.89

Métodos de Estimación

Analyst price target:$84.00
Discounted cash flow (DCF):$62.39
Earnings multiple (P/E):$59.46
Graham growth formula:$40.11
Earnings power value (EPV):$22.15
Justified P/B:$43.75
Dividend discount (Gordon):$29.62
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$60.80
Revenue multiple:Not enough data to compute it
Consenso de Analistas:Compra Fuerte (8B / 2H / 0S)
Última Sorpresa de Resultados:+6.95%

Métricas de Valoración

Ratio P/E

31.88

ROE

27.2%

Ratio P/B

11.66

P/FCF

31.00

Margen Bruto

-

ROIC

20.4%

Radar de Rentabilidad

Value Creation (Economic Moat)

ROIC

20.4%

WACC

8.1%

ROIC − WACC

+12.3 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Criterios de Análisis Fundamental

Superado (18)

  • EPS shows upward trend
  • Price CAGR 8.82%
  • ROIC 20.4%
  • Debt/Equity ratio
  • Operating Margin 20.2%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 27.9%
  • Revenue Growth 5Y 7.8%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 4.3%
  • Earnings Quality (OCF/NI) 1.06
  • Share Dilution -0.9%
  • Piotroski F-Score 5/9

Fallido (7)

  • EPS CAGR 2.16%
  • P/FCF 31.00
  • P/B Ratio 11.66
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 4.90
  • Net Margin Trend 17.7% vs 18.3%

No disponible (3)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-Score

5/9

Señales mixtas: algunas áreas requieren atención

score
criteria

Calidad de los Beneficios

1.06

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

-0.9%

Recomprando acciones. Favorable para el accionista

Gobernanza

Equipo Directivo

NombreCargoEdad
Dr. Catherine Ford Corrigan P.E., Ph.D.CEO & Director56
Mr. Richard L. Schlenker Jr.Executive VP, Corporate Secretary & Director59
Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D.Group Vice President56
Dr. Joseph Rakow Ph.D.Group Vice President48
Dr. Joseph Sala Ph.D.Group Vice President48
Dr. John D. Pye P.E., Ph.D.President54
Dr. Bernard Ross P.E., Ph.D.Co-Founder & Principal Engineer-
Mr. Eric R. AndersonChief Financial Officer50
Ms. Gina FlynnVP of Legal & General Counsel-
Mr. Brian KundertChief Human Resources Officer50

Riesgo de Auditoría

9

Riesgo del Consejo

2

Riesgo de Compensación

4

Riesgo de Derechos del Accionista

2

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Latest News

Recent headlines for EXPO, sourced from Markets Gazette.

No recent news for EXPO.